ENTITY
BeiGene

BeiGene (6160 HK)

303
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
16 Aug 2020 17:17

HSCI Index Rebalance - Stock Connect Flows Coming Up

The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 14 August....

Logo
476 Views
Share
bullishHuazhu Group
12 Aug 2020 14:36

Huazhu HK Secondary Listing - Early Look - Needs the Cash More than Most Secondary Candidates

Huazhu Group (HTHT US) has filed confidentially for a US$1bn secondary listing in Hong Kong, as per media reports. In our earlier insight, China...

Logo
492 Views
Share
bullishS&P 500 INDEX
22 Jul 2020 21:34

U.S. Equity Strategy: Bullish Outlook Intact

With the S&P 500 breaking above the June highs and the Russell 2000 bullishly inflecting topside a ~1-month base, it signals a continuation of...

Logo
386 Views
Share
bearishLuckin Coffee
30 Jun 2020 17:27
Smartkarma Originals

Short-Sell Strategies – How to Get Teflon Coated?

This insight has been produced jointly by Shifara Samsudeen, ACMA, CGMA ​and Supun Walpola ​at LightStream Research ​ In this Smartkarma...

Logo
893 Views
Share
22 Jun 2020 16:03

Yum China HK Listing - Early Look - Relatively Bigger Deal Should Have a Relatively Bigger Impact

Yum China Holdings, Inc (YUMC US)  has filed confidentially for a secondary listing in Hong Kong, as per media reports. It aims to raise around...

Logo
448 Views
Share
x